HURA · TuHURA Biosciences, Inc.

TuHURA Biosciences filed this 8-K/A to correct errors in the unaudited pro forma condensed combined financial statements previously filed on April 8, 2026, regarding the acquisition of Kineta. The acquisition, completed on June 30, 2025, was structured as a two-step merger where TuHURA acquired Kineta, including rights to the KVA12123 antibody (now TBS-2025). The merger consideration consisted of 2,868,169 shares of TuHURA common stock, with no fractional shares issued; cash was paid in lieu of fractions based on a $5.7528 per share value. Additionally, a concurrent private placement in June 2025 raised approximately $12.6 million through the sale of 4,759,309 shares and warrants to accredited investors at a combined price of $2.65 per unit. The warrants have an exercise price of $3.3125 and expire on December 3, 2030. The pro forma financials assume the merger occurred on January 1, 2025, and reflect TuHURA as the accounting acquirer. This amendment replaces the prior Exhibit 99.1 in its entirety and does not update any other aspects of the prior report. The corrected pro forma information is critical for investors to assess the combined company's financial position and performance.